Adjunctive Brivaracetam Therapy in Epilepsy: A Prospective Clinical Study: Adjunctive Brivaracetam Therapy in Epilepsy

Abdul Hafeez Bughio; Muslim Ali Lakhiar; Sajid Hussain Seelro; Noor Nabi Siyal; Neeta Maheshwary; Muhammad Iqbal Asif; Muhammad Athar

doi:10.54393/pjhs.v6i7.2771

Authors

Abdul Hafeez Bughio Department of Neurology, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan
Muslim Ali Lakhiar Department of Neurology, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan
Sajid Hussain Seelro Department of Neurology, Bilawal Medical College, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan
Noor Nabi Siyal Department of Neurology, Peoples University of Medical and Health Sciences, Nawabshah, Pakistan
Neeta Maheshwary Ziauddin University, Karachi, Pakistan
Muhammad Iqbal Asif Department of Medicine, Karachi Medical and Dental College, Karachi, Pakistan
Muhammad Athar Department of Community Medicine, Liaquat College of Medicine and Dentistry, Karachi, Pakistan

DOI:

https://doi.org/10.54393/pjhs.v6i7.2771

Keywords:

Adjunctive Brivaracetam, Epilepsy, Seizures, Anticonvulsants

Abstract

Epilepsy is one of those primary illnesses that affect the brain, and the population is estimated to be around 50 million people. Objective: To evaluate the efficacy and safety of adjunctive Brivaracetam therapy in adult patients with epilepsy. Methods: This observational, non-interventional, single-center study assessed the use of adjunctive Brivaracetam (BRV) in patients aged ≥16 years over six months (October 2023–March 2024). Eligible participants had stable antiepileptic drug (AED) regimens for at least one month before BRV initiation. Demographic data, seizure type, frequency, and intensity were documented at baseline, 3 months, and 6 months. The primary endpoint was the change in seizure frequency. Secondary outcomes included ≥50% seizure reduction, seizure freedom, and adverse events. Data were analyzed using SPSS version 23.0. Results: A total of 168 patients (mean age: 25.1 ± 12.9 years) received adjunctive BRV therapy. Partial seizures and comorbid depression were the most common indications for BRV use. Mean seizure frequency decreased from 5.26 ± 0.29 at baseline to 2.41 ± 0.24 at 3 months. All patients achieved seizure freedom by 6 months. Reported adverse effects were generally mild: somnolence 12 (7%), headache 10 (6%), and dizziness 9 (5%). Conclusions: Adjunctive BRV therapy demonstrated significant efficacy in reducing seizure frequency and achieving seizure freedom, with a favourable safety profile. These findings support BRV as a promising treatment option for patients with epilepsy unresponsive to conventional AEDs.

References

World Health Organization. Epilepsy [Internet]. 2024 Feb.

Bankole ND, Dokponou YC, De Koning R, Dalle DU, Kesici Ö, Egu C et al. Epilepsy Care and Outcome in Low-and Middle-Income Countries: A Scoping Review. Journal of Neurosciences in Rural Practice. 2024 Feb; 15(1): 8. doi: 10.25259/JNRP_527_2023.

International League Against Epilepsy. Conquering the Treatment Gap: Pakistan Starts Small, Stays Flexible, and Never Gives Up. Epigraph [Internet]. 2020 Winter; 22(1).

Matias MR. Development of New Antiepileptic Drug Candidates: A Set of Lamotrigine-Related Compounds (Doctoral Dissertation, Universidade da Beira Interior (Portugal)). 2018.

Epilepsy Society. Anti-seizure medication (ASM) [Internet]. 2020 Feb.

Khilari M, Nair PP, Jha BK. Brivaracetam: How Well Does It Fare as an Anti-Epileptic? A Review. Neurology India. 2021 Mar; 69(2): 284-93. doi: 10.4103/0028-3886.314584.

Chen Y, Li W, Lu C, Gao X, Song H, Zhang Y et al. Efficacy, Tolerability and Safety of Add-on Third-Generation Antiseizure Medications in Treating Focal Seizures Worldwide: A Network Meta-Analysis of Randomised, Placebo-Controlled Trials. E-Clinical Medicine. 2024 Apr; 70. doi: 10.1016/j.eclinm.2024.102513.

Feyissa AM. Brivaracetam in the Treatment of Epilepsy: A Review of Clinical Trial Data. Neuropsychiatric Disease and Treatment. 2019 Sep: 2587-600. doi: 10.2147/NDT.S143548.

Okada M, Fukuyama K, Shiroyama T, Ueda Y. Brivaracetam Prevents Astroglial L-Glutamate Release Associated with Hemichannel Through Modulation of Synaptic Vesicle Protein. Biomedicine and Pharmacotherapy. 2021 Jun; 138: 111462. doi: 10.1016/j.biopha.2021.111462.

Nicolas JM, Hannestad J, Holden D, Kervyn S, Nabulsi N, Tytgat D et al. Brivaracetam, A Selective High‐Affinity Synaptic Vesicle Protein 2A (SV 2A) Ligand with Preclinical Evidence of High Brain Permeability and Fast Onset of Action. Epilepsia. 2016 Feb; 57(2): 201-9. doi: 10.1111/epi.13267.

Biton V, Berkovic SF, Abou‐Khalil B, Sperling MR, Johnson ME, Lu S. Brivaracetam as Adjunctive Treatment for Uncontrolled Partial Epilepsy in Adults: A Phase III Randomized, Double‐Blind, Placebo‐Controlled Trial. Epilepsia. 2014 Jan; 55(1): 57-66. doi: 10.1111/epi.12433.

Klein P, Aboumatar S, Brandt C, Dong F, Krauss GL, Mizne S et al. Long-Term Efficacy and Safety from an Open-Label Extension of Adjunctive Cenobamate In Patients with Uncontrolled Focal Seizures. Neurology. 2022 Sep; 99(10): e989-98. doi: 10.1212/WNL.0000000000200792.

Lattanzi S, Canafoglia L, Canevini MP, Casciato S, Chiesa V, Dainese F et al. Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the Brivaracetam Add-on First Italian Network Study (BRIVAFIRST). Central Nervous System Drugs. 2021 Dec; 35(12): 1289-301.

Szaflarski JP, Besson H, D’Souza W, Faught E, Klein P, Reuber M et al. Effectiveness and Tolerability of Brivaracetam in Patients with Epilepsy Stratified by Comorbidities and Etiology in the Real World: 12-Month Subgroup Data from the International Experience Pooled Analysis. Journal of Neurology. 2024 Jun; 271(6): 3169-85. doi: 10.1007/s00415-024-12253-z.

Lattanzi S, Ascoli M, Canafoglia L, Paola Canevini M, Casciato S, Cerulli Irelli E et al. Sustained Seizure Freedom with Adjunctive Brivaracetam in Patients with Focal Onset Seizures. Epilepsia. 2022 May; 63(5): e42-50. doi: 10.1111/epi.17223.

Inoue Y, Tiamkao S, Zhou D, Cabral‐Lim L, Lim KS, Lim SH et al. Efficacy, Safety, and Tolerability of Adjunctive Brivaracetam in Adult Asian Patients with Uncontrolled Focal‐Onset Seizures: A Phase III Randomized, Double‐Blind, Placebo‐Controlled Trial. Epilepsia Open. 2024 Jun; 9(3): 1007-20. doi: 10.1002/epi4.12929.

World Health Organization. The use of the WHO-UMC System for Standardised Case Causality Assessment. Uppsala: The Uppsala Monitoring Centre. 2005 Jul; 1.

Siddiqui F, Soomro BA, Rehman EU, Numan A, Bano S, Salam JU et al. A Prospective, Observational, Multicentre Study to Evaluate the Efficacy of Brivaracetam as Adjuvant Therapy for Epilepsy: The Bravo Study. Drugs in Context. 2024 Jul; 13. doi: 10.7573/dic.2024-3-2.

Benbadis S, Klein P, Schiemann J, Diaz A, Elmoufti S, Whitesides J. Efficacy, Safety, and Tolerability of Brivaracetam with Concomitant Lamotrigine or Concomitant Topiramate in Pooled Phase III Randomized, Double-Blind Trials: A Post-Hoc Analysis. Epilepsy and Behavior. 2018 Mar; 80: 129-34. doi: 10.1016/j.yebeh.2017.12.024.

Brodie MJ, Fakhoury T, McDonough B, Colson AO, Stockis A, Elmoufti S et al. Brivaracetam-Induced Elevation of Carbamazepine Epoxide Levels: A Post-Hoc Analysis from the Clinical Development Program. Epilepsy Research. 2018 Sep; 145: 55-62. doi: 10.1016/j.eplepsyres.2018.06.002.

Ryvlin P, Dimova S, Elmoufti S, Floricel F, Laloyaux C, Nondonfaz X et al. Tolerability and Efficacy of Adjunctive Brivaracetam in Adults with Focal Seizures by Concomitant Antiseizure Medication Use: Pooled Results from Three Phase 3 Trials. Epilepsia. 2022 Aug; 63(8): 2024-36. doi: 10.1111/epi.17304.

Perucca E and Meador KJ. Adverse Effects of Antiepileptic Drugs. Acta Neurologica Scandinavica. 2005 Dec; 112: 30-5. doi: 10.1111/j.1600-0404.2005.00506.x.

Zaccara G, Giovannelli F, Giorgi FS, Franco V, Gasparini S, Benedetto U. Tolerability of New Antiepileptic Drugs: A Network Meta-Analysis. European Journal of Clinical Pharmacology. 2017 Jul; 73(7): 811-7. doi: 10.1007/s00228-017-2245-z.

Trinka E, Tsong W, Toupin S, Patten A, Wilson K, Isojarvi J et al. A Systematic Review and Indirect Treatment Comparison of Perampanel Versus Brivaracetam as Adjunctive Therapy in Patients with Focal-Onset Seizures with or Without Secondary Generalization. Epilepsy Research. 2020 Oct; 166: 106403. doi: 10.1016/j.eplepsyres.2020.106403.

Lattanzi S, Trinka E, Zaccara G, Striano P, Russo E, Del Giovane C et al. Third-Generation Antiseizure Medications for Adjunctive Treatment of Focal-Onset Seizures in Adults: A Systematic Review and Network Meta-Analysis. Drugs. 2022 Feb; 82(2): 199-218. doi: 10.1007/s40265-021-01661-4.

Yanes R, Briard JN, Nguyen TD, Sultanem M, Nguyen DK, Gibbs S et al. Prospective Post-Marketing Observational Study of Brivaracetam in People with Focal Epilepsy. Canadian Journal of Neurological Sciences. 2023 Dec:1-5. doi: 10.1017/cjn.2023.328.

Fisher RS, Blum DE, DiVentura B, Vannest J, Hixson JD, Moss R et al. Seizure Diaries for Clinical Research and Practice: Limitations and Future Prospects. Epilepsy and Behavior. 2012 Jul; 24(3): 304-10. doi: 10.1016/j.yebeh.2012.04.128.